Who
Kathleen Goin
Chief Operating Officer
Company insider
Files Form 4 as: Chief Operating Officer, Palvella Therapeutics.
In numbers
- Trades disclosed
- 155
- Buys
- 0
- Sells
- 12
- Bought
- $0
- Sold
- $10.8M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 13 Dec 2024
- Last trade
- 21 Oct 2026
- Last filed
- 23 Oct 2026
Companies traded
Activity over time
1 Nov 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 21 Oct 2026filed 23 Oct 2026 | PVLA Palvella TherapeuticsBiotechnology | SEC FORM 4 Code M | $15K2,165 at $7.14 | filing |
| 21 Oct 2026filed 23 Oct 2026 | PVLA Palvella TherapeuticsBiotechnology | SEC FORM 4 Code M | $20K2,148 at $9.08 | filing |
| 21 Oct 2026filed 23 Oct 2026 | PVLA Palvella TherapeuticsBiotechnology | SEC FORM 4 Sold | $253K2,043 at $123.62 | filing |
| 21 Oct 2026filed 23 Oct 2026 | PVLA Palvella TherapeuticsBiotechnology | SEC FORM 4 Sold | $208K1,663 at $125.16 | filing |
| 21 Oct 2026filed 23 Oct 2026 | PVLA Palvella TherapeuticsBiotechnology | SEC FORM 4 Sold | $77K607 at $126.19 | filing |
| 21 Oct 2026filed 23 Oct 2026 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,165 at $0.00 | filing |
| 21 Oct 2026filed 23 Oct 2026 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,148 at $0.00 | filing |
| 16 Sep 2026filed 18 Sep 2026 | PVLA Palvella TherapeuticsBiotechnology | SEC FORM 4 Code M | $15K2,154 at $7.14 | filing |
| 16 Sep 2026filed 18 Sep 2026 | PVLA Palvella TherapeuticsBiotechnology | SEC FORM 4 Code M | $20K2,148 at $9.08 | filing |
| 16 Sep 2026filed 18 Sep 2026 | PVLA Palvella TherapeuticsBiotechnology | SEC FORM 4 Sold | $251K1,659 at $151.16 | filing |
| 16 Sep 2026filed 18 Sep 2026 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,154 at $0.00 | filing |
| 16 Sep 2026filed 18 Sep 2026 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,148 at $0.00 | filing |
| 16 Sep 2026filed 18 Sep 2026 | PVLA Palvella TherapeuticsBiotechnology | SEC FORM 4 Sold | $151K989 at $152.36 | filing |
| 16 Sep 2026filed 18 Sep 2026 | PVLA Palvella TherapeuticsBiotechnology | SEC FORM 4 Sold | $253K1,654 at $153.24 | filing |
| 16 Sep 2026filed 18 Sep 2026 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,154 at $0.00 | filing |
| 16 Sep 2026filed 18 Sep 2026 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,148 at $0.00 | filing |
| 16 Sep 2026filed 18 Sep 2026 | PVLA Palvella TherapeuticsBiotechnology | SEC FORM 4 Code M | $15K2,154 at $7.14 | filing |
| 16 Sep 2026filed 18 Sep 2026 | PVLA Palvella TherapeuticsBiotechnology | SEC FORM 4 Code M | $20K2,148 at $9.08 | filing |
| 16 Sep 2026filed 18 Sep 2026 | PVLA Palvella TherapeuticsBiotechnology | SEC FORM 4 Sold | $251K1,659 at $151.16 | filing |
| 16 Sep 2026filed 18 Sep 2026 | PVLA Palvella TherapeuticsBiotechnology | SEC FORM 4 Sold | $151K989 at $152.36 | filing |
News
Insider Selling: Palvella Therapeutics (NASDAQ:PVLA) Director Sells $1,758,290.88 in StockPVLA · tickerreport.com · 17 Oct 2026Palvella Therapeutics to Present Phase 3 SELVA and Phase 2 TOIVA Results, Along With New Pediatric Analyses, at 2026 PeDRA Annual ConferencePVLA · manilatimes.net · 15 Oct 2026Palvella Therapeutics (NASDAQ:PVLA) Director Sells $935,202.64 in StockPVLA · themarketsdaily.com · 15 Oct 2026
0 headlines in the last 90 days name Kathleen Goin; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.